Plus   Neg

Integra LifeSciences Raises FY19 Adj. EPS Outlook, Q2 Profit Surges

While reporting financial results for the second quarter, medical technology company Integra LifeSciences Holdings Corp. (IART) on Wednesday continues to project fiscal 2019 earnings in a range of $1.46 to $1.53 per share. However, the company raised adjusted earnings guidance to a range of $2.70 to $2.75 per share from its prior range of $2.65 to $2.72 per share.

Further, the company maintained its full-year revenue guidance in the range of $1.515 billion to $1.525 billion on organic revenue growth of about 4 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $2.70 per share on revenues of $1.52 billion for the year. Analysts' estimates typically exclude special items.

For the second quarter, net income surged to $29.74 million or $0.34 per share from $11.38 million or $0.14 per share in the prior-year quarter. Adjusted earnings were $0.73 per share, compared to last year's $0.60 per share. Revenues increased 4.8 percent to $383.65 million from last year's $366.19 million. Organic revenue increased 6.6 percent.

Analysts expected quarterly earnings of $0.66 per share on sales of $373.29 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.
Follow RTT